Search | IOVS | ARVO Journals

View

Showing 1 – 19 of 19

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2015

Low luminance vision improves nearly twice as much as standard vision with ranibizumab for neovascular age-related macular degeneration

Ronald E P Frenkel; Anne E. Fung; Howard Shapiro; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5358. doi:

ARVO Annual Meeting Abstract June 2015

Visual acuity impairment under low luminance conditions at baseline is a powerful predictor of visual acuity response to ranibizumab therapy in patients with neovascular age-related macular degeneration

Marc C. Peden; Ronald E P Frenkel; Howard Shapiro; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5362. doi:

ARVO Annual Meeting Abstract April 2014

Low Luminance Visual Acuity and Treatment Response in Patients with wet Age-Related Macular Degeneration Enrolled in the HARBOR Study

Ronald E P Frenkel; Howard Shapiro; Ivo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3963. doi:

ARVO Annual Meeting Abstract March 2012

Clinical Detection of Optic Disc Hemorrhage

Melissa A. Knowles; Ronald E. Frenkel; Shahim Haji; Heather B. Seith; M.P.C. Frenkel

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):260. doi:

ARVO Annual Meeting Abstract March 2012

The Effect of Multiple Anti-VEGF Intravitreal Injections on Retinal Capillary Blood Flow

Shamim A. Haji; Heather B. Seith; Ronald E. Frenkel

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):868. doi:

ARVO Annual Meeting Abstract March 2012

Evaluation of Nerve Fiber Layer by SD-OCT in Patients Treated Monocularly with Anti-VEGF Intravitreal Injections for AMD

Heather B. Seith; Ronald E. Frenkel

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):876. doi:

ARVO Annual Meeting Abstract March 2012

Patient Pain Evaluation of Varying Anesthesia Methods and Needle Gauges for Intravitreal Injections

Ronald E. Frenkel; Heather B. Seith

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):887. doi:

ARVO Annual Meeting Abstract March 2012

Biological Feasibility Study for Implantable Continuous Intraocular Pressure Monitor

Kimberly A. Brown; Ronald E. Frenkel; Heather B. Seith; Esdras Arrieta; Jean-Marie Parel; M Jaeger; R Kline-Schroeder

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1995. doi:

ARVO Annual Meeting Abstract April 2011

Which Anesthesia Method is Best for Minimizing Pain from Intravitreal Injections?

Ronald E. Frenkel; Max P. Frenkel; Marlon J. Demeritt

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):1694. doi:

ARVO Annual Meeting Abstract April 2011

Predicting the Effect of Idiopathic Epiretinal Membranes on the Outcome of Phacoemulsification

Marlon J. demeritt; Ronald E. Frenkel; Max P. Frenkel

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):2155. doi:

ARVO Annual Meeting Abstract April 2010

Reproducibility of a New Optic Nerve and Sectoral Neuroretinal Rim Damage Assessment Scale in Patients with Glaucoma

R. E. Frenkel; S. A. Haji; M. Frenkel

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):2719. doi:

ARVO Annual Meeting Abstract April 2010

Phakic Eyes Have a Higher Risk of Developing Immediate IOP Spikes After Intravitreal (IVT) Injection of Anti-VEGF Drugs

S. A. Haji; M. M. P. Frenkel; R. E. Frenkel

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):5124. doi:

ARVO Annual Meeting Abstract April 2009

Continuous Monitoring of Intraocular Pressure with an Implantable Device

R. E. Frenkel; M. Jaeger; R. Kline-Schroeder; M. A. Latina; J. M. Parel; M. P. C. Frenkel

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):2858. doi:

ARVO Annual Meeting Abstract April 2009

The Effect of Prophylactic Use of IOP Lowering Medication on IOP Spikes After Intravitreal Injections

M. P. Frenkel; R. E. P. Frenkel; S. Haji

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):5020. doi:

ARVO Annual Meeting Abstract May 2008

Complications of a Surgeon’s Initial Intravitreal Injections

R. E. Frenkel; L. Mani; A. Reyes

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):253. doi:

ARVO Annual Meeting Abstract May 2008

Does Central Corneal Thickness Change When IOP Significantly Increases?

A. Giuliano; A. Reyes; L. Mani; R. E. P. Frenkel; A. R. Toler; M. P. C. Frenkel

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):277. doi:

ARVO Annual Meeting Abstract May 2007

Is IOP a Concern Post-Injection of Macugen, Avastin, or Lucentis?

A. R. Toler; R. E. P. Frenkel; L. Mani; M. P. C. Frenkel

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):74. doi:

ARVO Annual Meeting Abstract May 2007

Should We Be Concerned With Post-Injection IOP Spikes From Lucentis?

S. Schoenholtz; R. E. P. Frenkel; A. R. Toler; M. P. C. Frenkel

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):1268. doi:

ARVO Annual Meeting Abstract May 2007

Contralateral Effect from Intravitreal Avastin for the Treatment of Wet AMD

A. Giuliano; R. E. P. Frenkel; R. Avery; G. Thomas; A. R. Toler; M. P. C. Frenkel

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):3365. doi:

Advertisement